Adeyemi Oladipupo, Parker Nicole, Pointon Amy, Rolf Mike
AstraZeneca, R&D Biopharmaceuticals, Fleming Building (B623), Babraham Research Park, Babraham, Cambridgeshire CB22 3AT, United Kingdom.
AstraZeneca, R&D Oncology, Fleming Building (B623), Babraham Research Park, Babraham, Cambridgeshire CB22 3AT, United Kingdom.
J Pharmacol Toxicol Methods. 2020 Mar-Apr;102:106679. doi: 10.1016/j.vascn.2020.106679. Epub 2020 Jan 31.
The conscious telemetered rat is widely used as an early in vivo screening model for assessing the cardiovascular safety of novel pharmacological agents. The current study aimed to identify its utility in assessing electrocardiogram (ECG) PR and QRS interval changes.
Male Han-Wistar rats (~250 g) were implanted with radio-telemetry devices for the recording of ECG and haemodynamic parameters. Animals (n = 4-8) were treated with single doses of calcium (nifedipine, diltiazem or verapamil; CCBs) or sodium channel blockers (quinidine or flecainide; SCBs) or their corresponding vehicles in an ascending dose design. Data was recorded continuously up to 24 h post-dose. Pharmacokinetic analysis of blood samples was performed to allow comparison of effects to published data in other species.
Of the CCBs, only diltiazem (300 mg/kg) prolonged the PR interval (49 ± 2 versus vehicle: 43 ± 1 ms), although this was not statistically significant (p = .11). QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent. Both SCBs, caused statistically significant (p < .05) increases in both intervals - quinidine (100 mg/kg; PR: 50 ± 2 versus 43 ± 1 ms; QRS: 22 ± 2 versus 18 ± 1 ms) and flecainide (9 mg/kg; PR: 56 ± 1 versus 46 ± 1 ms; QRS: 27 ± 1 versus 21 ± 1 ms). Drug plasma exposure was confirmed in all animals.
At similar plasma concentrations to other species, the conscious telemetered rat demonstrates limited utility in assessing PR interval prolongation by CCBs, despite significant contractility effects being observed. However, results with SCBs demonstrate a potential application for evaluating drug-induced QRS prolongation.
清醒遥测大鼠被广泛用作评估新型药物心血管安全性的早期体内筛选模型。本研究旨在确定其在评估心电图(ECG)PR和QRS间期变化方面的效用。
雄性Han-Wistar大鼠(约250克)植入无线电遥测装置,用于记录心电图和血流动力学参数。动物(n = 4 - 8)以递增剂量设计接受单剂量钙通道阻滞剂(硝苯地平、地尔硫卓或维拉帕米;CCBs)或钠通道阻滞剂(奎尼丁或氟卡尼;SCBs)或其相应的赋形剂治疗。给药后连续记录数据直至24小时。对血样进行药代动力学分析,以便将结果与其他物种已发表的数据进行比较。
在CCBs中,只有地尔硫卓(300毫克/千克)延长了PR间期(49±2对赋形剂:43±1毫秒),尽管这在统计学上不显著(p = 0.11)。硝苯地平(30±1对24±0毫秒)和地尔硫卓(34±1对27±1毫秒)使QA间期缩短,但维拉帕米(30±0对37±1毫秒)使其延长,表明每种药物的药理活性。两种SCBs均使两个间期在统计学上显著增加(p < 0.05)——奎尼丁(100毫克/千克;PR:50±2对43±1毫秒;QRS:22±2对18±1毫秒)和氟卡尼(9毫克/千克;PR:56±1对46±1毫秒;QRS:27±1对21±1毫秒)。所有动物均证实有药物血浆暴露。
在与其他物种相似的血浆浓度下,清醒遥测大鼠在评估CCBs引起的PR间期延长方面效用有限,尽管观察到显著的收缩力效应。然而,SCBs的结果表明其在评估药物诱导的QRS间期延长方面有潜在应用。